Phase I/II Open Label Dose Escalation Study of the 17alpha-Hydroxylase/ C17,20-Lyase Inhibitor, Abiraterone Acetate in Hormone Refractory Prostate Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 17 Jun 2014
At a glance
- Drugs Abiraterone acetate (Primary) ; Dexamethasone; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Janssen Research & Development
- 10 Jun 2017 Biomarkers information updated
- 07 Sep 2012 Planned end date changed from 1 Oct 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.
- 31 Aug 2012 Planned end date changed from 1 May 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.